{
    "clinical_study": {
        "@rank": "127757", 
        "acronym": "REACH", 
        "arm_group": [
            {
                "arm_group_label": "BDP/FOR", 
                "description": "Patients receiving ICS/LABA therapy as FP/SAL (Seretide\u00ae) who, at an index prescription date (IPD): Change their therapy to BDP/FOR (Fostair\u00ae) at same or lower BDP-equivalent ICS dose"
            }, 
            {
                "arm_group_label": "FP/SAL", 
                "description": "Patients receiving ICS/LABA therapy as FP/SAL (Seretide\u00ae) who, at an index prescription date (IPD) : Remain on FP/SAL at the same BDP-equivalent ICS dose"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair\u00ae 100/6) is at\n      least equivalent in terms of exacerbation prevention to fluticasone dipropionate /\n      salmeterol (FP/SAL; Seretide\u00ae 125) in matched asthma patients switching to BDP/FOR following\n      treatment with FP/SAL in normal clinical practice compared with patients not switched."
        }, 
        "brief_title": "Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "To evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair\u00ae 100/6) is at\n      least equivalent in terms of exacerbation prevention to fluticasone dipropionate /\n      salmeterol (FP/SAL; Seretide\u00ae) in matched asthma patients switching to BDP/FOR following\n      treatment with FP/SAL in normal clinical practice compared with patients not switched. To\n      evaluate respiratory outcomes for Fostair in comparison to Seretide using a UK primary care\n      database (in patients switched for cost rather than clinical reasons)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged: 18-80 years 61-80 years to be non-smokers only\n\n          -  Evidence of asthma: a diagnostic code for asthma or two scripts for asthma..\n\n          -  Baseline FP/SAL therapy: \u22652 prescription for ICS/LABA therapy as FP/SAL\n\n          -  Evidence of Continuing Therapy: Include only patients who receive \u22652 prescriptions\n             for the therapy under study during the outcome year (i.e. \u22651 prescription at the\n             index date and \u22651 other). UK average is 3-4 prescriptions refilled per year, so \u22652\n             ensures capture of \"real-life\" data.\n\n          -  Evidence of Switching for economic reasons: FP/SAL patients from practices with \u22655\n             switches to Fostair in a 3 month period to minimise data taken from switching of\n             anomalous patients; optimal practices for inclusion are those switching \"wholesale\"\n             for economic reasons.\n\n        Exclusion Criteria:\n\n          -  Any chronic respiratory disease other than asthma\n\n          -  Are receiving maintenance oral steroid therapy during baseline period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All patients are diagnosed with asthma or COPD and aged between 18-80 years with all 61-80\n        year olds being non-smokers only"
            }
        }, 
        "enrollment": {
            "#text": "194723", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01908075", 
            "org_study_id": "R04312"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BDP/FOR", 
                    "FP/SAL"
                ], 
                "intervention_name": "FP/SAL", 
                "intervention_type": "Drug", 
                "other_name": "Seretide\u00ae"
            }, 
            {
                "arm_group_label": "BDP/FOR", 
                "intervention_name": "BDP/FOR", 
                "intervention_type": "Drug", 
                "other_name": "Fostair\u00ae 100/6"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fluticasone, salmeterol drug combination"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Primary care", 
            "Asthma management", 
            "Real-world", 
            "Observational", 
            "Fostair", 
            "Seretide"
        ], 
        "lastchanged_date": "July 24, 2013", 
        "link": [
            {
                "url": "http://www.optimumpatientcare.org/Html_Docs/OPCRD.html"
            }, 
            {
                "url": "http://www.cprd.com/intro.asp"
            }
        ], 
        "number_of_groups": "2", 
        "official_title": "REACH Fostair vs Seretide - Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management", 
        "overall_official": {
            "affiliation": "University of Aberdeen", 
            "last_name": "David Price", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Where an exacerbation is defined as:\n(i) Asthma-related\nHospital attendance / admissions OR\nAccident & Emergency (A&E) attendance OR (ii) Use of acute oral steroids.\nWhere:\n\u22651 oral steroid prescription occurs within 2 weeks of another, or\n\u22651 hospitalisation occurs within 2 weeks of another, or\n\u22651 hospitalisation occurs within 2 weeks of an oral steroid prescription", 
            "measure": "Exacerbations : rate ratio", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01908075"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Research in Real-Life Ltd", 
            "investigator_full_name": "David Price, Prof., MD", 
            "investigator_title": "Professor David Price", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Proxy Asthma Control.  The absence of exacerbation and the absence of antibiotic prescribing for lower respiratory tract infections (often a pragmatic prescribing decision taken by GPs in real world practice).\nControlled:\n(i) No Asthma-related:\nHospital attendance or admission\nA&E attendance, OR\nOut of hours attendance, OR\nOut-patient department attendance (ii) GP consultations for lower respiratory tract infection (iii) Prescriptions for acute courses of oral steroids\nUncontrolled:\n(i) All others.\na. Proxy Asthma Control + SABA As above, but with an additional criterion that limits \"controlled\" patients to those who use \u2264200mcg salbutamol daily.", 
                "measure": "Exacerbation control", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "As above, but with an additional criterion that limits \"controlled\" patients to those who use \u2264200mcg salbutamol daily", 
                "measure": "Proxy asthma control + SABA", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "No exacerbation and no change in therapy during the outcome year, where changes are:\n\u2022\u226550% increase in ICS dose relative to IPD dose, and/or\nChange in ICS/LABA drug within class, and/or\nChange in delivery device, and/or\nUse of additional (defined as not received during baseline year) therapy as defined by: theophylline, leukotriene receptor antagonists (LTRAs).", 
                "measure": "Treatment success", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Defined as proxy asthma control (above) plus:\nAverage daily prescribed dose of \u2264200mcg salubtamol / \u2264500mcg terbutaline", 
                "measure": "Asthma Control (including SABA)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Asthma-related hospitalizations\nDefinite: Hospitalisations coded with an asthma read code\nDefinite + Probable: Hospitalisations with an asthma read code + uncoded hospitalisations occurring within a 7-day window (either side of the hospitalisation date) of an asthma read code\nRespiratory hospitalisations\nDefinite: Hospitalisations coded with a lower respiratory code relevant for Paeds (for example J450)\nDefinite + Probable: Hospitalisations with an asthma read code + uncoded hospitalisations occurring within a 7-day window (either side of the hospitalisation date) of a lower respiratory read code", 
                "measure": "Hospitalisations", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "For ICS, defined as the number of days supply of ICS / 365 x 100%\nController/reliever ratio: number of controller units/ number of controller units + number of reliever units. Controllers are defined as ICS (including fixed combination ICS/LABA) and LTRA, while relievers are SABA. For ICS a unit is taken to be one inhaler; for LTRA a unit is one prescription.", 
                "measure": "Medication possession ratio", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Research in Real-Life Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Research in Real-Life Ltd", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}